Label Expansion

Johnson & Johnson Secures Tremfya FDA Joint Damage Label Expansion for Psoriatic Arthritis

By Regulatory Intelligence Desk
29 May 2026

The FDA has approved a label expansion for Johnson & Johnson’s TREMFYA® (guselkumab), cementing its position as the first IL-23 inhibitor with data showing it stops the progression of structural joint damage.

Tag: Label Expansion

Johnson & Johnson Secures Tremfya FDA Joint Damage Label Expansion for Psoriatic Arthritis

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement